Company news
Telo Genomics Corp. news in 2024
Telo Genomics Corp.'s news releases, calls and decks from 2024, newest first.
Telo Genomics Closes Oversubscribed $2.5 Million Private Placement
December 23, 2024
Telo Genomics Announces Private Placement for up to $2 Million
December 12, 2024
Telo Genomics Receives Approval from the Intellectual Property Ontario Program (IPON)
November 19, 2024
Telo Genomics Expands its Strategic Collaboration with Mayo Clinic
October 30, 2024
Telo Genomics Presents New Performance Data for Its Smoldering Myeloma Prognostic Test
October 22, 2024
Telo Genomics Assessing MRD Status in TELO-DMRD Study
September 10, 2024
Telo Genomics Receives CLIA Certification
August 13, 2024
Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP
June 18, 2024
Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024
June 12, 2024
Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology
May 30, 2024
Telo Genomics and Emery Pharma Announce Collaboration
May 15, 2024
Telo Genomics Receives Accreditation from College of American Pathologists
April 10, 2024
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial
April 2, 2024
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients
February 13, 2024
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US
January 30, 2024